Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the Second Quarter Ended June 30, 2020
July 21, 2020
Share
Genomma Lab Internacional, S.A.B. De C.V. Announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced sales was MXN 3,636.325 million compared to MXN 3,277.463 million a year ago. Operating income was MXN 714,850.000000 compared to MXN 63.283 million a year ago. Net income was MXN 360.817 million compared to MXN 243.175 million a year ago. For the half year, sales was MXN 6,970.861 million compared to MXN 6,415.314 million a year ago. Operating income was MXN 135.412 million compared to MXN 1.230 million a year ago. Net income was MXN 734.451 million compared to MXN 495.436 million a year ago.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
